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Value within otolaryngology 29Conclusion: Based on current evidence in the CEA registry, unilateral cochlear implantation for
hearing loss and CPAP for OSA are both cost-effective therapeutic interventions. Although
CUAs in otolaryngology have increased in quantity and improved in quality in more recent
years, there is a relative lack of CUAs in otolaryngology in comparison to other subspecialties.
Copyright ª 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on
behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-
SA license (http://creativecommons.org/licenses/by-nc-sa/4.0/).Introduction
The cost of medicine in the United States and abroad is
increasing at an exponential and economically unsustain-
able rate. Technological advances leading to more expen-
sive diagnostic and therapeutic tools have contributed to
this increase, which in turn has led to rising pressure to
demonstrate the value of such interventions. This has ul-
timately led to growing governmental, professional, orga-
nizational, and academic interests in the value propositions
in the healthcare system. Cost-effectiveness analysis (CEA)
is the primary modality by which investigators assess the
value of an intervention. CEA evaluates the price of an
intervention, either to the payer or to society, for an in-
dividual measure of effectiveness of that intervention.1
This can include the years of life added and quality of life
added, among others.
A subset of cost-effectiveness analysis is cost-utility
analysis (CUAs), which expresses the effectiveness of an
intervention using a uniform unit of cost per quality
adjusted life year (QALY). The QALY describes the time
spent in a certain health state, multiplied by the quality of
each state (with 1 QALY being perfectly healthy for one
year).2 In this way, both a treatment that improves health
related quality of life from 0.5 to 1.0 for 5 years and a
treatment that leads to 5 additional years of life with a
health condition of 0.5 both yield 2.5 QALYs. One general
way to look at value is to assess the cost of an intervention
and to correlate this with the benefits rendered, either in
life gained or in quality of life improved. In cost-utility
analysis, interventions are considered of favorable value
if their cost is less than $50,000 (USD) per QALY gained. As
the cost per QALY decreases, the intervention becomes
more cost effective. When comparing two interventions
with the same intended goal, the intervention with the
lower cost per QALY is the more economic choice.
Within all aspects of medical literature, there are an
increasing number of studies evaluating cost utility. How-
ever, this is challenging within subspecialties such as
otolaryngology due to a limited number of investigators and
conditions compared to other specialties. Nevertheless,
because otolaryngology utilizes costly diagnostic and ther-
apeutic strategies for managing conditions such as head and
neck cancer, hearing loss, and chronic sinusitis, it provides
a fertile landscape for the assessment of cost effective-
ness. The objectives of this study are to detail specific
characteristics of CUAs within otolaryngology, to evaluate
the quality of these studies and to summarize the collective
results of the most common topics of economic evaluations
in otolaryngology.Methods
We performed a quantitative and qualitative assessment of
studies within the spectrum of otolaryngology between 1976
and 2011 using the CEA registry.3 The CEA registry is a data-
base updated three times per year with publically available
data on all publications that are published in English, are
original cost-effectiveness analyses, and measure health
benefits of QALYs. The CEA registry is supported by the
Center for the Evaluation of Value and Risk in Health (CEVR)
and is part of the Institute for Clinical Research and Health
Policy Studies at Tufts Medical Center. The total number of
studies available in the registry at the time of analysis was
2913. The registry’s rigorous methodology for screening cost
utility analysis manuscripts is described on the website. In
short, a MEDLINE search is performed with the keywords,
“QALYs” “quality,” and “cost-utility analysis.” The CEA
registry teamscreens abstracts to assess if there is anoriginal
cost-utility estimate. Each article is then abstracted for
methodology, cost-effectiveness ratios, and utility weights.
Two trained readers audit each article independently and a
consensus audit resolves discrepancies.
Author MAC systematically reviewed all of the articles
within the CEA registry and screened for publications that
fall within the field of otolaryngology, which includes head
and neck surgery, endocrine surgery, otology, pediatric
otolaryngology, rhinology, allergy and sleep medicine. The
presence of an otolaryngologist author, as determined per
affiliations listed on the manuscript, was not a factor in
inclusion. In the unique case that affiliations were not
named, an Internet search was conducted. Study charac-
teristics, including year of publication, journal of publica-
tion, author affiliation, country of research, type of
funding, analysis perspective, intervention type, and CEA
registry quality score (numbered from 1 (low) to 7 (high) by
expert readers). The criteria used to determine the CEA
registry quality score of each study includes: 1. accurate
computation of incremental cost-effectiveness ratios, 2.
comprehensive characterization of the uncertainty of re-
sults, 3. explicit specification of health economic assump-
tions used in the study, and 4. appropriate and explicit
estimation of utility weights (Table 1). The strength and
direction of association between characteristics of each
study and CEA registry quality scores were measured using
the Pearson product moment correlation coefficient using
the Statistical Package for Social Sciences (SPSS Version
22.0, Chicago, IL). The collective results of CUAs of the
most commonly evaluated interventions were also assessed
in order to identify economically attractive management
options within otolaryngology.
Table 1 CEA registry quality score criteria, adapted from
the Tufts CEA Registry.3
CEA registry quality score criteria (in order of importance)
1 Did the study authors correctly compute the incremental
cost-effectiveness ratios?
2 Did the authors comprehensively characterize the un-
certainty of the results?
3 Were the health economic assumptions used in the study
(discount rate, currency, time horizon) explicitly
specified?
4 Was there an appropriate and explicit estimation of utility
weights?
Fig. 1 CUA publications per time period.
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Assessment of 2913 studies revealed 61CUAs that evaluated
interventions related to otolaryngology. The earliest study
was published in 1991 and assessed the cost-effectiveness
of tympanostomy tubes versus antibiotic prophylaxis for
acute otitis media (AOM). Eighty-five percent (52 of 61) of
studies were published later than 2000, with 28 (45.9%)Fig. 2 Publicationpublished between 2008 and 2011 (Fig. 1). The 61 publi-
cations addressed topics within the subspecialties of otol-
ogy (31.1%), endocrine surgery (19.6%), sleep medicine/
surgery (18.0%), head and neck surgery (13.0%), pediatric
otolaryngology (8.2%), allergy (6.6%), and rhinology (3.3%)
(Fig. 2). Of the 61 manuscripts related to otolaryngology, 18
(29.5%) studies had at least one author who was an
otolaryngologist. Eight (13.0%) manuscripts had a first
author and seven (11.4%) had a final author primarily
affiliated with a department of otolaryngology. Seventy-
two percent of publications with an otolaryngologist as a
first author were related to otology.
The otolaryngology CUAs were published in 41 journals,
with only five journals having three or more manuscripts
(Table 2). Thirty-two (52.4%) economic analyses had the
United States as the country of interest. Eight studies
focused on the United Kingdom and five on Canada. Ninety-
eight percent of manuscripts had at least one author with
an academic affiliation. Seventy-one percent of analyses
had the perspective of healthcare payer. The funding
sources of the manuscripts were stated as none or could not
be determined in 29 (47.5%), government funding in 17
(27.9%), pharmaceutical or device in 14 (22.9%), foundation
in 6 (9.8%) and healthcare organization in 3 (4.9%) (Table 2).
Two studies (3.3%) evaluated primary prevention strate-
gies, which are defined as efforts to prevent disease prior
to its occurrence. One of these primary prevention strate-
gies analyzed oral cancer screening programs for high-risk
males4 and the second evaluated candidate vaccines for
prevention of pediatric acute otitis media.5 Thirteen
studies assessed secondary prevention interventions
(methods that identify and treat asymptomatic individuals
with risk factors or preclinical disease) and 46 (75.4%)
evaluated tertiary prevention interventions (methods that
limit disability after harm has occurred). A majority of the
studies evaluated the cost utility of devices (47.5%) or
pharmaceuticals (29.5%) (Table 2).
The mean CEA registry quality score (on a scale of 1e7)
for all 61 studies was 4.00. A more recent publication year
was associated with a higher CEA registry quality score
(rZ 0.412, P < 0.01) (Table 3). The mean quality score forsubspecialties.
Table 2 Demographic characteristics of CUAs.
Study characteristic No. Studies
(%)
Mean CEA registry
quality score
(range)
Subspecialty
Otology 19 (31.1) 3.8 (1.5e6.0)
Endocrine surgery 12 (19.7) 4.2 (3.5e5.5)
Sleep medicine/surgery 11 (18.0) 4.2 (2.5e6.0)
Head and neck surgery 8 (13.0) 3.4 (2.5e5.0)
Pediatric otolaryngology 5 (8.2) 4.3 (3.0e5.5)
Allergy 4 (6.6) 4.5 (3.5e6.0)
Rhinology 2 (3.3) 4.5 (4.0e5.0)
Journal (2011 impact factor)
Laryngoscope (1.752) 6 (9.8) 3.3 (1.5e4.5)
Arch of Otolaryngology Head Neck Surg (1.63) 4 (6.6) 4.1 (1.5e5.0)
Ear Hearing (2.578) 3 (4.9) 4.5 (3.0e6.0)
Sleep (5.051) 3 (4.9) 4.2 (2.5e5.0)
Value Health (2.191) 3 (4.9) 5.0 (4.0e6.0)
Others 36 (59) 4.1 (1.5e6.0)
Total No. of Journals 41 4.0 (1.5e6.0)
Year of publication
1976e1991 1 (1.6) 3.0
1992e1995 4 (6.6) 2.1 (1.5e3.0)
1996e1999 4 (6.6) 3.9 (2e5.5)
2000e2003 10 (16.4) 3.9 (1.5e5.5)
2004e2007 14 (22.9) 4.0 (3.0e6.0)
2008e2011 28 (45.9) 4.4 (2.5e6.0)
Country of analysis
United States 32 (52.4) 3.9 (1.5e6.0)
United Kingdom 8 (13.1) 4.7 (1.5e6.0)
Canada 5 (8.2) 4.1 (2.5e5.5)
Australia 3 (4.9) 3.3 (3.0e4.0)
Germany 3 (4.9) 4.2 (4.0e4.5)
France 2 (3.3) 4.5 (3.5e5.5)
Netherlands 2 (3.3) 3.5 (2.0e5.0)
New Zealand 1 (1.6) 4.0
Austria 1 (1.6) 3.5
China 1 (1.6) 3.0
Finland 1 (1.6) 3.0
Belgium 1 (1.6) 5.0
Taiwan 1 (1.6) 5.0
Funding source
Government 17 (27.9) 4.1 (1.5e6.0)
Pharmaceutical or device 14 (22.9) 3.8 (1.5e5.5)
Could not be determined 29 (47.5) 3.9 (1.5e6.0)
Foundation 6 (9.8) 4.3 (3.0e5.5)
Healthcare organization 3 (4.9) 3.5 (1.5e4.5)
Perspective of study
Healthcare payer 43 (70.5) 3.9 (1.5e6.0)
Societal 17 (27.9) 4.4 (3.0e5.5)
Could not be determined 1 (1.6) 1.5
Intervention type
Primary 2 (3.3) 4.8 (4.0e5.5)
Secondary 13 (21.3) 3.8 (2.0e6.0)
Tertiary 46 (75.4) 4.0 (1.5e6.0)
Authors affiliation
Academic 60 (98.4) 4.0 (1.5e6.0)
Consultant 7 (11.5) 4.4 (3.5e5.0)
Government 1 (1.6) 3.0
(continued on next page)
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Table 2 (continued )
Study characteristic No. Studies
(%)
Mean CEA registry
quality score
(range)
Intervention assessed
Device 29 (47.5) 3.8 (1.5e6.0)
Diagnostic 6 (9.8) 4.0 (3.0e5.0)
Screening 6 (9.8) 3.4 (2.0e5.0)
Health education 1 (1.6) 4.0
Medical procedure 9 (14.7) 4.1 (3.0e5.0)
Pharmaceutical 18 (29.5) 4.6 (3.5e6.0)
Surgical 12 (19.7) 3.9 (2.5e5.5)
Immunization 2 (3.3) 5.0 (4.5e5.5)
Care delivery 2 (3.3) 3.3 (3.0e3.5)
Table 3 Correlations between CUA characteristics and
CEA registry quality score.
Variable Correlation
coefficient, r
P value
# of Otolaryngology authors 0.043 0.749
Publication year 0.412 0.001a
Journal impact factor 0.184 0.160
a Statistically significant.
32 K.R. Patel et al.studies with at least one otolaryngology author was 3.77
and 4.09 for those without an otolaryngology author. There
was no significant correlation between the number of
otolaryngologist authors and the CEA quality score. The
impact factor of the journal in which each study was pub-
lished also had no significant association with the quality of
the CUA. The references and topics for all 61 studies that
relate to otolaryngology in the CEA database are listed in
Table 4. Fourteen studies agreed on the cost-effectiveness
of at least unilateral cochlear implantation and 6 of 7
studies demonstrated CPAP to be a cost-effective strategy
for treating patients with OSA.Discussion
In an effort to limit healthcare expenditures and to allocate
resources efficiently, many groups have focused their work
on the economic appraisal of clinical interventions. As
healthcare costs rise, it remains unclear how the increasing
economic burden will be handled. There is an increasing
need for policy makers, administrators, and physicians alike
to evaluate the cost-effectiveness of the services provided.
Assessment of value has been investigated for decades,
with an exponential increase in cost effectiveness analyses
published in the past 10 years. Cost effectiveness research
in otolaryngology may have an especially profound impact
on limiting healthcare expenditures, as otolaryngologists
manage many conditions associated with high costs. The
cost of allergic rhinitis alone has been estimated to be close
to 5.3 billions dollars per year in the United States.6
Interestingly, these costs are far surpassed by that ofmanaging sinusitis, which impacts one in seven adults and
has direct costs alone estimated at 5.8 billion dollars per
year.7 Within otolaryngology, the management of head and
neck cancer and thyroid disease is also especially costly,
with only a portion of the costs reflected in direct expen-
ditures of imaging, surgery, and radiation therapy. As
healthcare costs continue to rise, it is vital that otolaryn-
gologists take on a more active role in assessing the cost
effectiveness of various management options as more
expensive innovative technologies continue to be
developed.
We have evaluated the CEA registry to assess the char-
acteristics, results and quality of CUAs, which include only
those studies measuring health benefits in QALYs, in
otolaryngology. Despite the high cost of managing condi-
tions in the practice of otolaryngology, only 2% of the total
CUA literature in the CEA registry evaluates intervention
sutilized by otolaryngologists and only 0.61% of the cost
utility literature in the CEA registry included an otolaryn-
gologist as an author. The relative paucity of otolaryngol-
ogists with published studies in the CEA registry may be
related to a relative infrequency of conditions with well-
established QALYs, fewer clinicians in otolaryngology with
training to perform these investigations, or perhaps
decreased awareness of these issues among otolaryngolo-
gists. Regardless of the reason, it is important that otolar-
yngologists become more involved in conducting these
studies in order to actively participate in discussions
regarding the allocation of heath care resources.
In a recent review assessing the quality of 50 economic
evaluations published in otolaryngology, Liu and colleagues
found that study characteristics such as journal impact
factor and presence of an author with a PhD in health
economics were associated with higher quality studies.8
Interestingly, in our study, the subjective quality score
bestowed by the CEA registry revealed no statistically sig-
nificant correlation between the quality of the manuscripts
and the number of otolaryngologist authors or the impact
factor of the journal in which the study was published. Our
review did reveal that studies with a more recent publica-
tion year are associated with a higher quality score, indi-
cating that despite the relative lack of CUAs related to
otolaryngology, the studies have been improving in both
quantity and quality in recent years. Assessment of the
Table 4 Summary of evaluated CUAs.
Year Specialty Journal Reference Topic of CUA publication
1991 General Fam Pract Res J Bisonni et al9 Tympanostomy tubes vs antibiotic
prophylaxis for AOM
1994 Sleep Sleep Tousignant et al10 Impact of nasal CPAP on quality of life
for OSA
1995 Otology Ann Otol Rhinol Laryngol Suppl Evans et al11 Adult unilateral cochlear implant
1995 Otology Med Prog Technol Lea et al12 Cochlear implantation vs vibrotactile
devices
1995 Otology Arch Otolaryngol Head Neck Surg Harris et al13 Cochlear implantation for profound
deafness
1996 Otology Laryngoscope Wyatt et al14 Multichannel cochlear implants
1996 Pediatrics Clin Ther Oh et al15 Second-line antibiotics for pediatric
AOM
1999 Otology Int J Technol Assess Health Care Carter et al16 Pediatric and adult cochlear
implantation
1999 Otology Arch Otolaryngol Head Neck Surg Palmer et al17 Adult cochlear implantation
2000 Otology Laryngoscope O’Neill et al18 Pediatric cochlear implantation
2000 Otology JAMA Cheng et al19 Pediatric cochlear implantation
2001 Head and neck Cancer Hollenbeak et al20 FDG-PET for N0 HNSCC
2002 Endocrine Eur J Endocrinol Vidal-Trecan et al21 Management of toxic thyroid
adenomas
2002 Otology Otol Neurotol Bichey et al22 Cochlear implantation for large
vestibular aqueduct syndrome
2002 Otology Laryngoscope Francis et al23 Cochlear implantation in older adults
2002 Head and neck Community Dent Oral Epidemiol Van der Meij et al24 Cancer screening of patients with oral
lichen planus
2002 Otology Arch Otolaryngol Head Neck Surg Summerfield et al25 Unilateral vs bilateral cochlear
implantation
2003 Otology Arch Otolaryngol Head Neck Surg Joore et al26 Fitting of hearing aids
2003 Otology Laryngoscope Wilson et al27 Intraoperative facial nerve
monitoring for otologic surgery
2004 Otology Ear Hear Group, UKCIS et al28 Unilateral cochlear implantation in
postlingually deafened adults
2004 Endocrine Thyroid Vidal-Trecan et al29 Radioiodine vs surgery for toxic
thyroid adenoma
2005 Endocrine Eur J Endocrinol Sejean et al30 Surgery vs medical follow-up for
primary hyperparathyroidism
2005 Endocrine ANZ J Surg Blamey et al31 Recombinant human TSH for diagnosis
of recurrent thyroid cancer
2005 Sleep Stroke Brown et al32 Sleep study screening of stroke
victims for OSA
2006 Pediatrics Pediatrics Van Howe et al33 Observation without testing for
pediatric pharyngitis
2006 Sleep Arch Int Med Ayas et al34 CPAP for moderate to severe OSA
2006 Otology Ear Hear Barton et al35 Pediatric cochlear implantation
2006 Endocrine Surgery Zanocco et al36 Management of asymptomatic
primary hyperparathyroidism
2007 Pediatrics Ann Fam Med Coco et al37 Management of pediatric acute otitis
media
2007 Endocrine Am J Kidney Dis Narayan et al38 Parathyroidectomy vs cinacalcet for
hyperparathyroidism in ESRD
2007 Allergy Curr Med Res Opin Keiding et al39 Immunotherapy for seasonal allergic
rhinoconjunctivitis
2007 Rhinology Am J Rhinol Anzai et al40 Management of acute sinusitis
2007 Otology Genet Med Veenstra et al41 Testing for mitochondrial mutation
(A155G) in cystic fibrosis
2008 Sleep J Int Med Res Lojander et al42 Nasal CPAP for OSA
2008 Otology Otol Neurotol Chang et al43 Hearing aid outcome in the elderly
2008 Allergy Ann Allergy Asthma Immunol Bruggenjurgen et al44 Subcutaneous immunotherapy for
(continued on next page)
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Table 4 (continued )
Year Specialty Journal Reference Topic of CUA publication
allergic rhinitis and allergic asthma
2008 Head and neck Value Health Brown et al45 Cetuximab plus radiotherapy for head
and neck cancer
2008 Sleep Thorax Guest et al46 CPAP for OSA
2008 Sleep Can Respir J Tan et al47 CPAP for OSA
2008 Endocrine Surgery Zanocco et al48 Parathyroidectomy vs observation for
primary hyperparathyroidism
2009 Endocrine Value Health Mernagh et al49 Recombinant human TSH before RAI
ablation for thyroid cancer
2009 Head and neck Ann Oncol Sher et al50 CT and PET-CT for determining need
for neck dissection in HNSCC
2009 Head and neck Dermatol Surg Seidler et al51 Mohs vs traditional surgery for
nonmelanoma skin cancer
2009 Rhinology Appl Health Encon Health Policy Kneis et al52 Sinfrontal, homeopathic medication,
for acute maxillary sinusitis
2009 Head and neck Acad Radiol Yen et al53 MRI vs PET vs MRI-PET for diagnosis of
recurrent NPC
2009 Sleep Int J Technol Assess Health Care Weatherly et al54 CPAP vs dental devices and lifestyle
advice for OSA
2009 Allergy Am J Epidemiol Witt et al55 Acupuncture for allergic rhinitis
2009 Sleep Sleep Breath Sadatsafavi et al56 CPAP vs oral appliances for OSAH
2009 Otology Fam Pract Hernandez et al57 Management of Bell’s palsy
2009 Pediatrics Pediatrics O’Brien et al5 Candidate vaccines for prevention of
pediatric AOM
2009 Sleep Sleep Snedecor et al58 Eszopiclone for primary chronic
insomnia
2009 Endocrine J Am Coll Surg In et al59 Treatment options for Graves disease
2010 Endocrine Ann Surg Oncol Wang et al60 Oral calcium and calcitriol following
total thyroidectomy
2010 Otology Ear Hear Summerfield et al61 Bilateral pediatric cochlear
implantation
2010 Endocrine JCEM Wang et al60 Recombinant TSH prior to RAI for
thyroid cancer
2010 Allergy Value Health Petrou et al62 Topical intranasal steroids for
pediatric OME
2011 Sleep Sleep Pietzsch et al63 Diagnostic and therapeutic strategies
for OSA
2011 Sleep Cost Eff Resour Alloc Scott et al64 Treatment of insomnia
2011 Endocrine JCEM Li et al65 Novel molecular test for
indeterminate thyroid nodules
2011 Head and neck Laryngoscope Higgins et al66 Radiation vs transoral laser surgery
for early-stage glottic carcinoma
2011 Head and neck Laryngoscope Dedhia et al4 Oral cancer screening programs for
high-risk males
Abbreviations: AOM, acute otitis media; PAP, continuous positive airway pressure; T, computed tomography; CUA, cost-utility analysis;
ESRD, end stage renal disease; FDG-PET, 18-F fluoro-2-deoxyglucose positron emission tomography; HNSCC, head and neck squamous cell
carcinoma; MRI, magnetic resonance imaging; NPC, nasopharyngeal carcinoma; OME, otitis media with effusion; OSA, obstructive sleep
apnea; OSAH, obstructive sleep apnea-hypopnea; PET-CT, positron emission tomography-computed tomography; TSH, thyroid stimu-
lating hormone; RAI, radioiodine.
34 K.R. Patel et al.topics addressed by all of the studies and their collective
results revealed that unilateral cochlear implantation is
cost effective in all settings evaluated. Furthermore, 86% of
studies identified CPAP to be a cost effective strategy for
the management of OSA (Table 3).
Although the relatively large number of studies evalu-
ated and the use of the CEA registry make this reviewunique, there are several limitations. The CEA registry is a
limited database with regards to cost effectiveness litera-
ture as a whole. It is possible that many other cost-
effectiveness analyses related to otolaryngology that do
not adhere to the stringent CUA criteria, yet have made
important contributions to understanding the cost of in-
terventions in otolaryngology, have not been evaluated in
Value within otolaryngology 35this particular study. We did not perform our own manual
search of all English literature to ensure that no publica-
tions were missing from the CEA registry, nor did we
perform our own assessment of the individual studies
included in this study. Despite this, we are the first group to
perform a review of the CUA literature in otolaryngology
that has fit the inclusion criteria of the CEA registry. Future
reviews of CUAs in otolaryngology may wish to combine
search results from multiple databases in order to more
comprehensively review the literature in this field.
Conclusion
Based on current evidence in the CEA registry, there is
consensus that unilateral cochlear implantation for hearing
loss and near consensus that CPAP for OSA are both cost
effective interventions. Although CUAs in otolaryngology
have increased in quantity and quality in more recent
years, there is a lack of CUAs evaluating interventions in
otolaryngology. A significant need exists for more otolar-
yngologists to become involved in evaluating the cost
effectiveness of the therapeutic interventions they utilize.
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